commercial weight loss

Weight Watchers Expands Collaboration With Novo Nordisk

July 2, 2025 Weight Watchers announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through Weight Watchers Clinic. As part of the collaboration, Weight Watchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, which serves as the dispensing pharmacy for the […]

Weight Watchers Expands Collaboration With Novo Nordisk Read More »

Weight Watchers Prepares for Possible Bankruptcy Filing

News / John LaRosa

April 9, 2025 (Reuters) – WW International may be preparing to file for bankruptcy in the coming months as part of a plan to hand control of the business to its creditors, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Shares of the company tumbled nearly 59% to 18 cents

Weight Watchers Prepares for Possible Bankruptcy Filing Read More »

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion

News / John LaRosa

March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over

News / John LaRosa

Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over Read More »

Medifast Reports Q4 and Full Year 2024 Results

News / John LaRosa

Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO. Fourth quarter 2024 revenue decreased 37.7% to $119.0

Medifast Reports Q4 and Full Year 2024 Results Read More »

The Party Is Almost Over for GLP-1 Compounders

Uncategorized / John LaRosa

January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the

The Party Is Almost Over for GLP-1 Compounders Read More »

Herbalife Weight Management Sales Continue Slide

Uncategorized / John LaRosa

November 20, 2024 Herbalife’s sales of weight management products in North America continue to decline, most likely due to strong competition from the GLP-1 weight loss drugs. Total U.S. sales for the 9 months ended Sept. 30, 2024 were down 7.9%, and North American sales represented 21% of the total. Total weight management sales from

Herbalife Weight Management Sales Continue Slide Read More »

Weight Watchers Reports 3rd Quarter Results

News / John LaRosa

Nov. 6, 2024 WW (Weight Watchers) reported results for the 3rd quarter 2024 today. “For over six decades, Weight Watchers has been the trusted leader in weight management, offering a full spectrum of science-backed, proven weight management solutions. With our expanded clinical offering, iconic trusted brand, and global community of members, we are well-equipped to

Weight Watchers Reports 3rd Quarter Results Read More »

Medifast Reports 3rd Quarter Results

News / John LaRosa

Nov. 4, 2024 Medifast reported Q3 results today. CEO Dan Chard said: “With tailored plans, personal solutions and a focused approach to driving customer acquisition, we believe that our strategy can drive sustainable growth in the quarters and years ahead.” Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672

Medifast Reports 3rd Quarter Results Read More »

Invisible Medical Groups Are Behind GLP-1 Boom

News / John LaRosa

October 17, 2024 According to State Health, the telehealth GLP-1 boom wouldn’t be possible without clinicians willing to write prescriptions for those hundreds of thousands of patients. Companies are rarely transparent — with patients or the public — about the medical groups behind the screens. But a STAT examination found that just a handful of networks of

Invisible Medical Groups Are Behind GLP-1 Boom Read More »

(813) 971-8080